Pharma Intelligence, Simplified

← All Targets

NK1R

7 drugs

Market Leader

GLENMARK SPECLT

2

approved indications

7

Approved Drugs

6

Companies

4

Indications

0

Therapeutic Areas

Top Drugs

GLENMARK SPECLT

2 indications · 2012

2 indications · 2023

2 indications · 2015

Unlock Full Target Intelligence PRO

✓ Competitive landscape by company (6 companies)

✓ All 7 approved drugs

✓ Therapeutic area breakdown

✓ Full indication list (4 indications)

✓ Patent cliff analysis

✓ Clinical trials pipeline

Starting at $99/mo

Unlock with Pro →

Drugs by Company

HERON THERAPS INC 2 drugs

GLENMARK SPECLT 1 drug

STERISCIENCE 1 drug

By Therapeutic Area

Other 7 drugs

Drugs by Company PRO

HERON THERAPS INC 2 drugs

CINVANTI APONVIE

GLENMARK SPECLT 1 drug

STERISCIENCE 1 drug

TERSERA 1 drug

Bayer 1 drug

Merck 1 drug

By Therapeutic Area

Other 7 drugs

APREPITANT, FOCINVEZ, VARUBI, LYNKUET +3 more

Indications Treated

NauseaVomitingVasomotor SymptomsMenopause

All Drugs Targeting NK1R

Drug	Company	Approved	Indications	Therapeutic Area
APREPITANT	GLENMARK SPECLT	2012	2
FOCINVEZ	STERISCIENCE	2023	2
VARUBI	TERSERA	2015	2
LYNKUET	Bayer	2025	2
EMEND	Merck	2003	2
CINVANTI	HERON THERAPS INC	2017	2
APONVIE	HERON THERAPS INC	2022	-